Table 1.
Comparison of baseline characteristics among the 4 age groups
| Characteristic | 0-5 y | 6-12 y | 13-18 y | ≥ 19 y | Total | P for overall comparison of the 4 age groups | Significant pairwise comparisons* |
|---|---|---|---|---|---|---|---|
| No. of patients | 66 | 69 | 65 | 1072 | 1272 | ||
| Treatment arm | .65 | ||||||
| Lower dose | 23 (35) | 19 (28) | 26 (40) | 349 (33) | 417 (33) | ||
| Medium dose | 25 (38) | 26 (38) | 18 (28) | 354 (33) | 423 (33) | ||
| Higher dose | 18 (27) | 24 (35) | 21 (32) | 369 (34) | 432 (34) | ||
| Sex | .34 | ||||||
| Male | 41 (62) | 40 (58) | 46 (71) | 641 (60) | 768 (60) | ||
| Female | 25 (38) | 29 (42) | 19 (29) | 431 (40) | 504 (40) | ||
| Age, y | 3.2 (2.2, 4.6) | 8.9 (7.4, 11.7) | 15.6 (14.8, 16.7) | 52.3 (41.6, 60.4) | 48.8 (31.9, 59.0) | NA | |
| Weight, kg | 14.2 (11.9, 17.6) | 30.9 (24.6, 38.5) | 63.9 (55.2, 82.5) | 81.1 (69.2, 94.2) | 78.1 (63.0, 92.2) | < .001 | |
| Height, cm | 96.1 (85.0, 102.6) | 131 (122.5, 145.7) | 168.2 (162.0, 176.0) | 171.6 (164.0, 178.0) | 170 (161.0, 177.0) | < .001 | |
| BSA, m2 | 0.6 (0.5, 0.7) | 1.0 (0.9, 1.3) | 1.8 (1.6, 2.0) | 2.0 (1.8, 2.1) | 1.9 (1.7, 2.1) | < .001 | |
| Disease treatment category | < .001 | A, B, C, E, F | |||||
| Autologous or syngeneic stem cell transplantation | 29 (44) | 12 (17) | 12 (18) | 376 (35) | 429 (34) | ||
| Allogeneic stem cell transplantation | 27 (41) | 45 (65) | 39 (60) | 412 (38) | 523 (41) | ||
| Chemotherapy without HSCT for hematologic malignancy | 7 (11) | 11 (16) | 11 (17) | 284 (26) | 313 (25) | ||
| Chemotherapy without HSCT for solid tumor† | 3 (5) | 1 (1) | 3 (5) | 0 (0) | 7 (1) | ||
| Primary diagnosis | < .001 | A, B, C, E, F | |||||
| Acute lymphocytic leukemia | 9 (14) | 19 (28) | 14 (22) | 74 (7) | 116 (9) | ||
| Acute myelogenous leukemia | 11 (17) | 22 (32) | 25 (38) | 411 (38) | 469 (37) | ||
| Chronic myelogenous leukemia | 1 (2) | 2 (3) | 6 (9) | 45 (4) | 54 (4) | ||
| Chronic lymphocytic leukemia | 0 (0) | 0 (0) | 0 (0) | 21 (2) | 21 (2) | ||
| Chronic myelomonocytic leukemia | 0 (0) | 0 (0) | 0 (0) | 6 (1) | 6 (< 1) | ||
| Non-Hodgkin lymphoma | 1 (2) | 8 (12) | 5 (8) | 190 (18) | 204 (16) | ||
| Hodgkin lymphoma | 0 (0) | 2 (3) | 2 (3) | 75 (7) | 79 (6) | ||
| Myelodysplastic syndromes | 0 (0) | 0 (0) | 0 (0) | 74 (7) | 74 (6) | ||
| Plasma cell disorders | 0 (0) | 0 (0) | 0 (0) | 157 (15) | 157 (12) | ||
| Non–hematopoietic solid tumor carcinoma | 9 (14) | 0 (0) | 1 (2) | 4 (< 1) | 14 (1) | ||
| Non–hematopoietic solid tumor sarcoma | 0 (0) | 1 (1) | 3 (5) | 1 (< 1) | 5 (< 1) | ||
| Non–hematologic solid tumor (nonsarcoma, noncarcinoma) | 24 (36) | 5 (7) | 5 (8) | 3 (< 1) | 37 (3) | ||
| Aplastic anemia congenital and acquired | 5 (8) | 7 (10) | 3 (5) | 9 (1) | 24 (2) | ||
| Other | 6 (9) | 3 (4) | 1 (2) | 2 (< 1) | 12 (1) | ||
| Desired type of platelets | < .001 | B, C, E | |||||
| Apheresis | 62 (94) | 57 (83) | 51 (78) | 711 (66) | 881 (69) | ||
| Pooled whole blood–derived platelet concentrates | 4 (6) | 12 (17) | 14 (22) | 361 (34) | 391 (31) | ||
| Previous platelet transfusion | < .001 | C, E, F | |||||
| Yes | 60 (91) | 59 (86) | 55 (85) | 550 (52) | 724 (57) | ||
| No | 6 (9) | 10 (14) | 10 (15) | 517 (48) | 543 (43) | ||
| Unknown | 0 | 0 | 0 | 5 | 5 | ||
| Previous RBC transfusion | < .001 | C, E, F | |||||
| Yes | 63 (95) | 65 (94) | 60 (92) | 768 (72) | 956 (75) | ||
| No | 3 (5) | 4 (6) | 5 (8) | 300 (28) | 312 (25) | ||
| Unknown | 0 | 0 | 0 | 4 | 4 | ||
| Spleen | .72 | ||||||
| Splenectomy | 3 (5) | 1 (1) | 1 (2) | 28 (3) | 33 (3) | ||
| Enlarged | 2 (3) | 1 (1) | 1 (2) | 49 (5) | 53 (4) | ||
| Not enlarged | 61 (92) | 67 (97) | 63 (97) | 995 (93) | 1186 (93) | ||
| Laboratory values | |||||||
| Hemoglobin level, g/dL | 9.4 (8.7, 10.6) | 10 (8.9, 10.7) | 9.8 (8.9, 11.5) | 9.8 (9.1, 10.7) | 9.8 (9.0, 10.7) | .23 | |
| Unknown | 1 | 0 | 0 | 3 | 4 | ||
| Hematocrit, % | 27.3 (24.2, 30.0) | 28 (26.0, 30.8) | 27.6 (25.9, 32.6) | 28.3 (26.0, 31.0) | 28 (26.0, 31.0) | .05 | |
| Unknown | 1 | 0 | 0 | 8 | 9 | ||
| Platelet count, 103/μL | 91 (44.0, 155.0) | 50 (25.0, 147.0) | 44 (25.0, 105.0) | 36 (25.0, 54.0) | 38 (25.0, 61.0) | < .001 | B, C, E, F |
| Unknown | 1 | 0 | 0 | 3 | 4 | ||
| PT, × upper limit of normal | 0.96 (0.89, 1.02) | 0.96 (0.90, 1.04) | 1.01 (0.93, 1.07) | 0.91 (0.83, 0.97) | 0.92 (0.84, 0.99) | < .001 | C, E, F |
| Unknown | 11 | 9 | 12 | 170 | 202 | ||
| INR | 1 (0.9, 1.1) | 1 (1.0, 1.1) | 1 (1.0, 1.2) | 1.1 (1.0, 1.1) | 1 (1.0, 1.1) | .02 | C |
| Unknown | 1 | 0 | 0 | 13 | 14 | ||
| No. with neither PT nor INR | 1 | 0 | 0 | 11 | 12 | .77 | |
| PTT, sec | 32.2 (29.0, 34.8) | 31.3 (28.9, 35.0) | 32.7 (29.9, 36.7) | 28.7 (26.0, 32.0) | 29 (26.2, 32.7) | < .001 | C, E, F |
| Unknown | 1 | 0 | 0 | 11 | 12 | ||
| Fibrinogen level, mg/dL | 306 (29.0, 357.0) | 328 (266.0, 422.0) | 344 (276.0, 410.0) | 369 (283.0, 480.0) | 360 (278.5, 466.5) | < .001 | B, C, E, F |
| Unknown | 1 | 0 | 0 | 15 | 16 | ||
| Lymphocytotoxic antibody screen‡ | |||||||
| 0% | 50 (79) | 55 (83) | 53 (85) | 736 (74) | 894 (75) | .04 | A |
| 1%-19% | 4 (6) | 9 (14) | 6 (10) | 156 (16) | 175 (15) | ||
| ≥ 20% | 9 (14) | 2 (3) | 3 (5) | 107 (11) | 121 (10) | ||
| Unknown | 3 | 3 | 3 | 73 | 82 |
Values for categorical variables are presented as n (%); values for continuous variables are presented as median (quartile 1, quartile 3).
INR indicates international normalized ratio; and NA, not applicable.
*
A: 0-5 years vs 6-12 years; B: 0-5 years vs 13-18 years; C: 0-5 years vs ≥ 19 years; D: 6-12 years vs 13-18 years; E: 6-12 years vs ≥ 19 years; F: 13-18 years vs ≥ 19 years.
†
Excluded from analyses of interaction between age group and disease treatment category because of small sample sizes.
‡
Patients already known to have panel reactive antibody ≥ 20% were excluded from PLADO. However, some patients were found to have values ≥ 20% on the study's baseline test.